XML 120 R57.htm IDEA: XBRL DOCUMENT
v3.25.1

Significant transactions (Details) € in Thousands, $ in Thousands |  |  |  |  |  |  |  |  | 1 Months Ended | 12 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 29, 2024 USD ($) | Dec. 22, 2023 EUR (€) | Dec. 04, 2023 USD ($) | Jul. 07, 2023 USD ($) | Oct. 18, 2022 EUR (€) | Jan. 01, 2021 | Feb. 03, 2020 USD ($) | Dec. 21, 2018 USD ($) | Jun. 30, 2021 USD ($) patient | Mar. 31, 2019 EUR (€) | Jan. 31, 2019 | Oct. 31, 2018 EUR (€) | Dec. 31, 2024 EUR (€) | Dec. 31, 2024 USD ($) | Dec. 31, 2023 EUR (€) | Dec. 31, 2022 EUR (€) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2024 USD ($) | Dec. 22, 2023 USD ($) | Oct. 12, 2023 EUR (€) | Jul. 19, 2023 USD ($) | Dec. 31, 2021 EUR (€) | Dec. 31, 2021 USD ($) | Jul. 31, 2018 EUR (€)
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment upon second regulatory approval | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 750 |  |  |
Increase in loans and conditional advances | € |  |  |  |  |  |  |  |  |  |  |  |  | € 0 |  | € 150 | € 0 |  |  |  |  |  |  |  |  |  |
Loans repayments | € |  |  |  |  |  |  |  |  |  |  |  |  | 3,075 |  | 2,971 | 3,642 |  |  |  |  |  |  |  |  |  |
Prepaid expenses | € |  |  |  |  |  |  |  |  |  |  |  |  | 3,195 |  | 2,560 |  |  |  |  |  |  |  |  |  |  |
Capital increases | € |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 60,154 | € 0 |  |  |  |  |  |  |  |  |  |
Non-current financial liabilities | € |  |  |  |  |  |  |  |  |  |  |  |  | 45,978 |  | € 45,543 |  |  |  |  |  |  |  |  |  |  |
EIB fixed rate loan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase in loans and conditional advances | € |  |  |  |  |  |  |  |  |  | € 14,000 |  | € 16,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Borrowings, interest rate |  |  |  |  |  |  |  |  |  | 5.00% |  | 6.00% |  |  | 21.30% | 21.30% |  |  |  |  |  |  |  |  |  |
Undrawn borrowing facilities | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 10,000 |  |
Royalties agreement, period |  |  |  |  | 6 years | 6 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining notional amount | € |  |  |  |  | € 25,300 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales threshold | € |  |  |  |  | 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued interest | € |  |  |  |  | 5,400 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 5,400 |  |  |  |
Milestone payment | € |  |  |  |  | € 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,000 |  |  |  |
First installment period |  |  |  |  | 1 year |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Second installment period |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Prorated payment, maximum percentage of milestone payment |  |  |  |  | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Borrowings, cumulative milestone prepayment amount | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 100,000 |  |  |  |
Loans repayments | € |  |  |  |  |  |  |  |  |  |  |  |  | 200 |  | € 800 |  |  |  |  |  |  |  |  |  |  |
Non-current financial liabilities | € |  |  |  |  |  |  |  |  |  |  |  |  | € 19,000 |  | 19,200 | € 27,500 |  |  |  |  |  |  |  |  |  |
Maximum | Event One |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment increase | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,200 |  |  |  |  |  |  |
Maximum | Event Two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment increase | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 16,400 |  |  |  |  |  |  |
First Tranche | EIB fixed rate loan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Borrowings, interest rate |  |  |  |  | 6.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining notional amount | € |  |  |  |  | € 16,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Second Tranche | EIB fixed rate loan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Borrowings, interest rate |  |  |  |  | 5.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining notional amount | € |  |  |  |  | € 9,300 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Second Tranche | EIB fixed rate loan, tranche two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Remaining notional amount | € |  |  |  |  | € 9,300 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Top of Range | EIB fixed rate loan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Notional amount | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 40,000
Maximum | EIB fixed rate loan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Notional amount | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 40,000
Janssen |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, upfront payment license fee | $ |  |  |  | $ 30,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, success-based payment | $ |  |  |  | 1,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from milestone payment | $ | $ 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, equity investment receivable | $ |  |  | $ 4,800 | 20,200 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capital increases | $ |  |  |  | 30,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Janssen | EIB fixed rate loan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Borrowings, interest rate |  |  |  |  |  |  |  |  |  |  |  |  | 21.30% |  |  |  |  |  |  | 21.30% |  |  |  |  |  |
Janssen | First Tranche |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, equity investment receivable | $ |  |  |  | 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Janssen | Second Tranche |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, equity investment receivable | $ |  |  |  | 25,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Janssen | Top of Range |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential development and commercial milestones payments | $ |  |  |  | 650,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, compensation per indication | $ |  |  |  | 220,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Janssen | Nanobiotix Corp. | Top of Range |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, compensation per indication | $ |  |  |  | $ 220,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
LianBio, NBTXR3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received | $ |  |  |  |  |  |  |  |  | $ 20,000 |  |  |  |  |  |  |  |  | $ 20,000 |  |  |  |  |  |  |  |
Collaboration agreement, amount collected | € |  |  |  |  |  |  |  |  |  |  |  |  | € 1,100 |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | € |  | € 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
LianBio, NBTXR3 | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential development and commercial milestones payments | $ |  |  |  |  |  |  |  |  | $ 205,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
LianBio, NBTXR3 | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential development and commercial milestones payments | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 225,000 |  |  |  | $ 205,000 |
Termination of PharmaEngine License and Collaboration Agreement, NBTXR3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,500 |  |  |  |  |  |  |  |
Contractual commitments, cumulative payments | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,500 |
Milestone payment upon second regulatory approval | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,000 |  |  |  |  |  |
Royalties agreement, period |  |  |  |  |  |  |  |  |  |  |  |  | 10 years | 10 years |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment upon receipt of clinical study reports | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000 |  |  | $ 1,000 |  |  |  |  |  |  |  |  |
MD Anderson Cancer Center, NBTXR3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of transactions between related parties [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ |  |  |  |  |  |  | $ 1,000 | $ 1,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patients | patient |  |  |  |  |  |  |  |  | 312 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual capital commitments | $ |  |  |  |  |  |  |  | $ 11,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment, deferment period |  |  |  |  |  |  |  |  |  |  | 6 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Prepaid expenses | € |  |  |  |  |  |  |  |  |  |  |  |  | € 1,200 |  | € 1,200 |  |  |  |  |  |  |  |  |  |  |

X
- Definition The interest rate on borrowings. [Refer: Borrowings] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 7 -IssueDate 2024-01-01 -Paragraph 7 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_BorrowingsInterestRate
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ContractualCapitalCommitments
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_CurrentPrepaidExpenses
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of non-current financial liabilities. [Refer: Financial liabilities] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2024-01-01 -Paragraph 25 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_NoncurrentFinancialLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The nominal or face amount of a financial instrument, used to calculate payments made on that instrument. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_NotionalAmount
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from borrowings obtained. [Refer: Borrowings] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 7 -IssueDate 2024-01-01 -Paragraph 17 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ProceedsFromIssueOfOrdinaryShares
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph d -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_d&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2024-01-01 -Paragraph 50 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_a&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_UndrawnBorrowingFacilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Borrowings, Cumulative Milestone Prepayment Amount + References No definition available. + Details
Name: | nbx_BorrowingsCumulativeMilestonePrepaymentAmount
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Borrowings, Milestone Payment Contigency + References No definition available. + Details
Name: | nbx_BorrowingsMilestonePaymentContigency
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Borrowings, Milestone Payment, First Installment Period + References No definition available. + Details
Name: | nbx_BorrowingsMilestonePaymentFirstInstallmentPeriod
Namespace Prefix: | nbx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Borrowings, Milestone Payment, Second Installment Period + References No definition available. + Details
Name: | nbx_BorrowingsMilestonePaymentSecondInstallmentPeriod
Namespace Prefix: | nbx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Borrowings, Net Sales Threshold + References No definition available. + Details
Name: | nbx_BorrowingsNetSalesThreshold
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Borrowings, Prorated Payment, Maximum Percentage Of Milestone Payment + References No definition available. + Details
Name: | nbx_BorrowingsProratedPaymentMaximumPercentageOfMilestonePayment
Namespace Prefix: | nbx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Borrowings, Remaining Notional Amount + References No definition available. + Details
Name: | nbx_BorrowingsRemainingNotionalAmount
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Agreement, Collected + References No definition available. + Details
Name: | nbx_CollaborationAgreementCollected
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement, Equity Investment Compensation + References No definition available. + Details
Name: | nbx_CollaborationAgreementEquityInvestmentCompensation
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement, Potential Milestones Payments To Be Received + References No definition available. + Details
Name: | nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceived
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration Agreement, Potential Milestones Payments To Be Received Per Indication + References No definition available. + Details
Name: | nbx_CollaborationAgreementPotentialMilestonesPaymentsToBeReceivedPerIndication
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Agreement, Success-Based Payment + References No definition available. + Details
Name: | nbx_CollaborationAgreementSuccessBasedPayment
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement, Upfront Payment License Fee + References No definition available. + Details
Name: | nbx_CollaborationAgreementUpfrontPaymentLicenseFee
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement, Upfront Payment Received + References No definition available. + Details
Name: | nbx_CollaborationAgreementUpfrontPaymentReceived
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contractual Commitments, Cumulative Payments + References No definition available. + Details
Name: | nbx_ContractualCommitmentsCumulativePayments
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contractual Commitments, Milestone Payment, Annual Increase + References No definition available. + Details
Name: | nbx_ContractualCommitmentsMilestonePaymentAnnualIncrease
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contractual Commitments, Milestone Payment Upon Receipt Of Clinical Study Reports + References No definition available. + Details
Name: | nbx_ContractualCommitmentsMilestonePaymentUponReceiptOfClinicalStudyReports
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contractual Commitments, Milestone Payment Upon Second Regulatory Approval + References No definition available. + Details
Name: | nbx_ContractualCommitmentsMilestonePaymentUponSecondRegulatoryApproval
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contractual Commitments, Payment + References No definition available. + Details
Name: | nbx_ContractualCommitmentsPayment
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Interest Payable, Payment-In-Kind + References No definition available. + Details
Name: | nbx_InterestPayablePaymentInKind
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone Payment, Deferment Period After Enrollment + References No definition available. + Details
Name: | nbx_MilestonePaymentDefermentPeriodAfterEnrollment
Namespace Prefix: | nbx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Patients In Clinical Trial + References No definition available. + Details
Name: | nbx_NumberOfPatientsInClinicalTrial
Namespace Prefix: | nbx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds From Milestone Payment + References No definition available. + Details
Name: | nbx_ProceedsFromMilestonePayment
Namespace Prefix: | nbx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalties Agreement, Period + References No definition available. + Details
Name: | nbx_RoyaltiesAgreementPeriod
Namespace Prefix: | nbx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_EventAxis=nbx_EventOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_EventAxis=nbx_EventTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_TranchesAxis=nbx_FirstTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_TranchesAxis=nbx_SecondTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BorrowingsByNameAxis=nbx_EuropeanInvestmentBankLoanAgreementTrancheTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_CollaborationAgreementAxis=nbx_JanssenPharmaceuticaNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=nbx_NanobiotixCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_CollaborationAgreementAxis=nbx_LianBioNBTXR3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_CollaborationAgreementAxis=nbx_TerminationOfPharmaEngineLicenseAndCollaborationAgreementNBTXR3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nbx_CollaborationAgreementAxis=nbx_MDAndersonCancerCenterNBTXR3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |